Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Revenue (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Revenue data on record, last reported at $121000.0 in Q4 2025.

  • For Q4 2025, Revenue fell 89.7% year-over-year to $121000.0; the TTM value through Dec 2025 reached $1.5 million, down 77.99%, while the annual FY2025 figure was $1.5 million, 77.99% down from the prior year.
  • Revenue reached $121000.0 in Q4 2025 per CLDX's latest filing, up from -$1000.0 in the prior quarter.
  • Across five years, Revenue topped out at $4.1 million in Q4 2023 and bottomed at -$1000.0 in Q3 2025.
  • Average Revenue over 5 years is $1.1 million, with a median of $690000.0 recorded in 2021.
  • Peak YoY movement for Revenue: skyrocketed 1374.58% in 2021, then plummeted 100.03% in 2025.
  • A 5-year view of Revenue shows it stood at $334000.0 in 2021, then soared by 382.93% to $1.6 million in 2022, then soared by 156.11% to $4.1 million in 2023, then crashed by 71.56% to $1.2 million in 2024, then plummeted by 89.7% to $121000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $121000.0 in Q4 2025, -$1000.0 in Q3 2025, and $730000.0 in Q2 2025.